The Innovative Medicines Initiative, a joint undertaking of the European Union and the European Federation of Pharmaceutical Industries and Associations, launched OPTIMA, a €21.3 million public-private research program that will seek to use artificial intelligence to improve care for patients with prostate, breast, and lung cancer.
To access this subscriber-only content please log in or renew your subscription.
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe